Monoclonal antibodies that selectively recognize methamphetamine and methamphetamine like compounds
View Patent ↗The invention generally relates to monoclonal antibodies that recognize at least one compound from the group consisting of (+) methamphetamine, (+) amphetamine, and (+) 3,4-methylenedioxymethamphetamine ((+) MDMA). Generally speaking, the monoclonal antibodies do not recognize (−) methamphetamine, (−) amphetamine, or (−) MDMA.
1. An isolated monoclonal antibody that recognizes each compound of the group consisting of (+)amphetamine, (+)methamphetamine, and (+)3,4-methylenedioxymethamphetamine, and does not substantially recognize each compound of the group consisting of (−)amphetamine, (−)methamphetamine, and (−)3,4-methylenedioxymethamphetamine, wherein the antibody is generated using a immunizing agent comprising the formula
2. The isolated monoclonal antibody of claim 1 , wherein the antibody has an IC 50 ratio calculated in reference to (+)methamphetamine of less than about 12% for each compound of the group consisting of (−)amphetamine, (−) methamphetamine, and (−)3,4-methylenedioxymethamphetamine.
3. The isolated monoclonal antibody of claim 1 , wherein the antibody has an IC 50 ratio calculated in reference to (+)methamphetamine of greater than about 25% for each compound of the group consisting of (+)amphetamine, (+)methamphetamine, and (+)3,4-methylenedioxymethamphetamine.
4. The isolated monoclonal antibody of claim 3 , wherein the antibody has an IC 50 ratio calculated in reference to (+)methamphetamine of less than about 12% for each compound of the group consisting of (−)amphetamine, (−) methamphetamine, and (−)3,4-methylenedioxymethamphetamine.
5. The isolated monoclonal antibody of claim 1 , wherein the heavy chain of the antibody comprises the amino acid sequence of SEQ ID NO:25, and the light chain of the antibody comprises the amino acid sequence of SEQ ID NO:26.
6. The isolated monoclonal antibody of claim 1 , wherein the heavy chain of the antibody comprises the amino acid sequence of SEQ ID NO:19, and the light chain of the antibody comprises the amino acid sequence of SEQ ID NO:21.
7. The isolated monoclonal antibody of claim 1 , wherein the antibody is selected from the group consisting of a murine antibody, a human antibody, a humanized antibody, a chimeric antibody, a recombinant antibody, and an antigen binding fragment of an antibody.
8. A method of treating drug use in a subject, the method comprising administering a monoclonal antibody of claim 1 to the subject, wherein the monoclonal antibody decreases the concentration of (+)amphetamine, (+)methamphetamine, and (+)3,4-methylenedioxymethamphetamine in the brain of the subject.
9. The method of claim 8 , wherein the subject is selected from the group comprising a rodent, a non-human primate, and a human.
10. A method of treating drug use in a subject, the method comprising administering a monoclonal antibody of claim 1 to the subject, wherein the monoclonal antibody decreases the concentration of (+)amphetamine, (+)methamphetamine, or (+)3,4-methylenedioxymethamphetamine in the brain of the subject.
11. The method of claim 10 , wherein the subject is selected from the group comprising a rodent, a non-human primate, and a human.
12. A method for detecting the presence of at least one compound in a sample selected from the group of compounds consisting of (+)methamphetamine, (+)amphetamine, and (+)3,4-methylenedioxymethamphetamine, the assay comprising contacting the sample with a monoclonal antibody of claim 1 and detecting the association of the monoclonal antibody in the sample with at least one compound selected from the group consisting of (+)methamphetamine, (+)amphetamine, and (+)3,4-methylenedioxymethamphetamine.
13. The method of claim 12 , wherein the sample is a biological sample or a chemical sample.
14. The method of claim 13 , wherein the biological sample is a biological fluid.
15. The method of claim 12 , wherein the association is detected by a means selected from the group consisting of ELISA, immunochromatographic assay, and immunoprecipitation assay.
16. The method of claim 12 , wherein the assay further comprises quantifying the amount of a compound selected from the group of compounds consisting of (+)methamphetamine, (+)amphetamine, and (+)3,4-methylenedioxymethamphetamine in the sample.
17. A kit, wherein the kit comprises a monoclonal antibody that recognizes each compound of the group consisting of (+)amphetamine, (+)methamphetamine, and (+)3,4-methylenedioxymethamphetamine, and does not substantially recognize each compound of the group consisting of (−)amphetamine, (−) methamphetamine, and (−)3,4-methylenedioxymethamphetamine, wherein the antibody is generated using a immunizing agent comprising the formula